A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ILs / immunoliposomes

[Related PubMed/MEDLINE]
Total Number of Papers: 16
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ILs  (>> Co-occurring Abbreviation)
Long Form:   immunoliposomes
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A new immune-nanoplatform for promoting adaptive antitumor immune response. mAbs, PD-L1
2018 Clinical translation of immunoliposomes for cancer therapy: recent perspectives. ---
2015 Immunoliposomes for Targeted Delivery of an Antifibrotic Drug. DFO, FAP, PEG, scFv
2013 Monoclonal antibody-based therapies in cancer: advances and challenges. ADCs, ITs
2013 Targeted antiepidermal growth factor receptor (cetuximab) immunoliposomes enhance cellular uptake in vitro and exhibit increased accumulation in an intracranial model of glioblastoma multiforme. EGFR, GBM
2013 Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells. B-CLL, dILs
2012 Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. DOX, EGFR, MDR
2012 Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. PLD, VEGFR2
2011 Single application of low-dose mycophenolate mofetil-OX7-immunoliposomes ameliorates experimental mesangial proliferative glomerulonephritis. ECM, MMF
10  2011 The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma. i.v
11  2009 pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells. NIPAM
12  2006 EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. EGFR
13  2003 Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. EGFR
14  2001 Tumor targeting using anti-her2 immunoliposomes. DOX, mAb
15  2000 Emerging antibody-based HER2 (ErbB-2/neu) therapeutics. ADEPT, dox, Ls
16  1997 Anti-HER2 immunoliposomes for targeted therapy of human tumors. DOX